Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NV30NpZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn0TWM2OD1yLkC2NUDPxE1? NIPBZZpUSU6JRWK=
ALL-PO MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXzcYJKSzVyPUCuNFY{PTVizszN NHHFdHZUSU6JRWK=
697 NInYcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXqS|E4UUN3ME2wMlA6QTd4IN88US=> MUXTRW5ITVJ?
NCI-H748 M4TjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;nVGlEPTB;MD6xNFM{PCEQvF2= NUi0dGJYW0GQR1XS
NKM-1 M{HycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT1TI1mUUN3ME2wMlExQTF{IN88US=> NEDpWYJUSU6JRWK=
ES1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMUGyOVUh|ryP NVPWclJZW0GQR1XS
NCI-H1963 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUG1O|kh|ryP Mk\hV2FPT0WU
NCI-H1417 M3HIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TGUGlEPTB;MD6xNlk4PCEQvF2= NEKz[JRUSU6JRWK=
NEC8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMUO1Nlch|ryP NHzNbIxUSU6JRWK=
CRO-AP2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjSVWpKSzVyPUCuNVY5QDlizszN MkXXV2FPT0WU
A3-KAW NWrlUXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7mTWM2OD1yLkG3OlI4KM7:TR?= MWjTRW5ITVJ?
SF539 NYW4UVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yyNGlEPTB;MD6xPVU6OyEQvF2= M1jPOnNCVkeHUh?=
NOS-1 M4P0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDuTWM2OD1yLkG5OlE6KM7:TR?= M3fueXNCVkeHUh?=
NTERA-S-cl-D1 NWftNGZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnSTWM2OD1yLkKwNVE{KM7:TR?= MlfaV2FPT0WU
COR-L88 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PJbGlEPTB;MD6yNlk2QSEQvF2= MX3TRW5ITVJ?
EM-2 NGrOOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWwTWM2OD1yLkK0NFc6KM7:TR?= M4rQW3NCVkeHUh?=
KARPAS-45 NGXsV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHmTWM2OD1yLkK3PFM{KM7:TR?= NYTXXHV[W0GQR1XS
DSH1 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;0TWM2OD1yLkK4O|A5KM7:TR?= MWHTRW5ITVJ?
HT-144 NYTGc455T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\VPWlEPTB;MD6zNFI2PiEQvF2= M1rCS3NCVkeHUh?=
ATN-1 NUTJenhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmxXI04UUN3ME2wMlMxPTd4IN88US=> NWW2NoZ4W0GQR1XS
HEL MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ETWM2OD1yLkOxN|Q5KM7:TR?= NHzEW3ZUSU6JRWK=
NB12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfmVpdKSzVyPUCuN|E4PTZizszN M{focHNCVkeHUh?=
LU-139 M1LZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\BSYp7UUN3ME2wMlM{PTFizszN MlriV2FPT0WU
J-RT3-T3-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LmV2lEPTB;MD6zN|cyPiEQvF2= M4LtUnNCVkeHUh?=
MOLT-13 M4C0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwM{O4NUDPxE1? NGLy[lZUSU6JRWK=
SR M1PDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwM{SyOlEh|ryP MWHTRW5ITVJ?
CMK MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NViwXFFCUUN3ME2wMlM2PzJ5IN88US=> NVXhOWg1W0GQR1XS
ES8 NX3Qe|JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;je2lEPTB;MD6zOlAzOiEQvF2= NWPtT|hjW0GQR1XS
LB647-SCLC NFvkcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrNZoZuUUN3ME2wMlM3PzNizszN MVXTRW5ITVJ?
TE-8 M2DJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHKNmFKSzVyPUCuN|Y6OzVizszN NXTPRng3W0GQR1XS
BV-173 NYe1WZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXLOodKSzVyPUCuN|cyOjFizszN NWHMVpZuW0GQR1XS
DEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW1RWpKSzVyPUCuN|c1QDdizszN NUPqbVA4W0GQR1XS
ARH-77 NF3aTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\oTWM2OD1yLkO4NVk{KM7:TR?= NWPwTJI3W0GQR1XS
NCCIT NEXHOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn5PYlEUUN3ME2wMlM5PjR7IN88US=> M1e5cnNCVkeHUh?=
RPMI-8402 NHP2fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13CZWlEPTB;MD6zPFcxOSEQvF2= M4XqdnNCVkeHUh?=
MONO-MAC-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHnOZpFUUN3ME2wMlM5Pzd4IN88US=> M2PqPHNCVkeHUh?=
SK-MM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn4S4xKSzVyPUCuN|k5PjhizszN NWrle3JKW0GQR1XS
CHP-126 M1y2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNECyN|Eh|ryP NGD2cIdUSU6JRWK=
A101D NYDGTWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNECzJO69VQ>? NGPQfHNUSU6JRWK=
SCH NF3wcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwNECzOFIh|ryP M3y4T3NCVkeHUh?=
NMC-G1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK1R4xCUUN3ME2wMlQxOzZ5IN88US=> NVfZUIR5W0GQR1XS
NCI-H209 NHrwSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixWWk6UUN3ME2wMlQxPjF|IN88US=> MVTTRW5ITVJ?
MOLT-16 NUeySIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjQc|F7UUN3ME2wMlQyODF5IN88US=> MUPTRW5ITVJ?
RPMI-6666 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNEGxNkDPxE1? NVHWOGRKW0GQR1XS
OPM-2 NXK4UJN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjwTWM2OD1yLkSxOVE{KM7:TR?= MUPTRW5ITVJ?
MRK-nu-1 M37qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T2VGlEPTB;MD60N|E2OyEQvF2= M3XmTnNCVkeHUh?=
BC-1 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nnUmlEPTB;MD60N|QxOyEQvF2= NIO1eWVUSU6JRWK=
MHH-NB-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnkTWM2OD1yLkSzOFU{KM7:TR?= M4TWVnNCVkeHUh?=
Ramos-2G6-4C10 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37TNWlEPTB;MD60N|g6PyEQvF2= M4jLOXNCVkeHUh?=
LS-513 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7tUnF3UUN3ME2wMlQ1PTBzIN88US=> NEnROWhUSU6JRWK=
K5 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwNEewNlUh|ryP NYPucpE2W0GQR1XS
HOP-62 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwNEizOVgh|ryP M{Tj[HNCVkeHUh?=
NCI-H187 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD1yLkS5NlI4KM7:TR?= MoHBV2FPT0WU
BE-13 M2[yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNEm2OlEh|ryP NH7BeohUSU6JRWK=
HC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNUC0O|Mh|ryP MW\TRW5ITVJ?
ACN M161U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrKO49KSzVyPUCuOVExOjhizszN MULTRW5ITVJ?
HCC1599 NV73fW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W2WGlEPTB;MD61NVU4KM7:TR?= M1nFNXNCVkeHUh?=
MV-4-11 M1n0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2xTWM2OD1yLkWzNFQyKM7:TR?= MmLIV2FPT0WU
LC-2-ad MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37ZRmlEPTB;MD61N|Y3OyEQvF2= NW\yN2EzW0GQR1XS
HL-60 M1LiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG5dFFuUUN3ME2wMlU1OjZzIN88US=> MUTTRW5ITVJ?
NB17 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnVSGRlUUN3ME2wMlU1OzhizszN MmO1V2FPT0WU
TE-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXrfYVKSzVyPUCuOVU{ODZizszN NYfYTHRYW0GQR1XS
NCI-H524 NGjWT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNUW0NFEh|ryP NIjy[3VUSU6JRWK=
MZ7-mel NEX6eZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkiyTWM2OD1yLkW2NVA2KM7:TR?= NEjmUpRUSU6JRWK=
L-363 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHuVJlpUUN3ME2wMlU3PjV5IN88US=> NFnhZXhUSU6JRWK=
BL-41 NXG3TYlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPCPGdKSzVyPUCuOVY5QDlizszN MY\TRW5ITVJ?
LU-134-A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInZOHpKSzVyPUCuOVcxPzNizszN MV3TRW5ITVJ?
SIG-M5 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnflTWM2OD1yLkW3PFQ5KM7:TR?= MnvHV2FPT0WU
ONS-76 NX;uTHBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWyTWM2OD1yLkW4NlQzKM7:TR?= MkHaV2FPT0WU
KARPAS-299 NF\DV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GzXmlEPTB;MD61PFUxPCEQvF2= M4rhfXNCVkeHUh?=
DU-4475 NVXIboJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNUi3NFMh|ryP M2LUVXNCVkeHUh?=
NB69 NF;odVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPQTWM2OD1yLkW5PFI2KM7:TR?= MYDTRW5ITVJ?
MHH-PREB-1 NXvJXW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNkC3NVkh|ryP Mn\UV2FPT0WU
LU-165 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNkG4NVIh|ryP Moi2V2FPT0WU
LOUCY MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PrS2lEPTB;MD62N|M3PCEQvF2= MlnFV2FPT0WU
NCI-H526 M1nNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwNkO1OFEh|ryP NFjQXYlUSU6JRWK=
KE-37 M{\jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnBNHFKSzVyPUCuOlQzPzZizszN NUf5[JFvW0GQR1XS
NALM-6 NHPNTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Pn[2lEPTB;MD62OFg3KM7:TR?= M{HieXNCVkeHUh?=
CW-2 M3:4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nHfmlEPTB;MD62OVc6PCEQvF2= MorOV2FPT0WU
SU-DHL-1 NGj3botIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rhOmlEPTB;MD62OVk1PyEQvF2= MVjTRW5ITVJ?
NB13 NEPX[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\YPGlEPTB;MD62OlgyPyEQvF2= MmXuV2FPT0WU
QIMR-WIL NInqOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3lNlZKSzVyPUCuOlg{PDNizszN M3\3UHNCVkeHUh?=
ECC12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\QTWM2OD1yLkewNFg3KM7:TR?= NUfPTIJWW0GQR1XS
KALS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\RTohwUUN3ME2wMlcxPDl{IN88US=> MljkV2FPT0WU
COR-L279 NI\UeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPNTWM2OD1yLkewPVk3KM7:TR?= MmfQV2FPT0WU
NB14 NVzK[3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwN{K2NVch|ryP Mkn0V2FPT0WU
CCRF-CEM NGewUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG0TWM2OD1yLke0OlYyKM7:TR?= NEH6fHRUSU6JRWK=
SW954 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHSZnZKSzVyPUCuO|U6QTlizszN MnX0V2FPT0WU
IST-SL1 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwN{ezOFgh|ryP MnzZV2FPT0WU
LAMA-84 NGH1U3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjHTlhKSzVyPUCuO|c2PjdizszN NVjm[VlKW0GQR1XS
Daudi NEC5S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFfHlKSzVyPUCuO|c3QDFizszN NVmxfo95W0GQR1XS
BC-3 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnRb4p3UUN3ME2wMlc5OzB6IN88US=> NXfxdYxqW0GQR1XS
HCC2998 M4nFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\uTWM2OD1yLke4N|Yh|ryP M3H6dHNCVkeHUh?=
NCI-H69 NXvPVpUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwOECxOFch|ryP MlvrV2FPT0WU
CPC-N NFvGeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXqbGJoUUN3ME2wMlgxPTJ2IN88US=> MWfTRW5ITVJ?
NOMO-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DWemlEPTB;MD64NVA5PCEQvF2= MU\TRW5ITVJ?
CESS MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;GTWM2OD1yLkixNVk4KM7:TR?= Mnz5V2FPT0WU
LC4-1 NFXFeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzEfohKSzVyPUCuPFQxODdizszN Ml\BV2FPT0WU
BL-70 NXzsfYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jlOGlEPTB;MD64OVcxOiEQvF2= NWLSUGxsW0GQR1XS
ES4 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXDT3NKSzVyPUCuPFU5PjhizszN M4H1cnNCVkeHUh?=
HCE-T MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwOEexO|Eh|ryP NYTsOIN6W0GQR1XS
JAR MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yzWmlEPTB;MD64O|gzPyEQvF2= MYnTRW5ITVJ?
ST486 M1v4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;zTXQ6UUN3ME2wMlg4QTF5IN88US=> MXrTRW5ITVJ?
KS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPHS|RKSzVyPUCuPFgxQTZizszN NYj3W5dKW0GQR1XS
GDM-1 M1XzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XnVGlEPTB;MD64PFY5PyEQvF2= NHXXOVJUSU6JRWK=
EHEB NIPqU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXqPWhwUUN3ME2wMlkzPTh3IN88US=> NVi1TXpKW0GQR1XS
LB2518-MEL M3r4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\kTWM2OD1yLkmzNlg1KM7:TR?= NITYXHZUSU6JRWK=
GOTO M4[wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOUWwO|Yh|ryP M2fZcHNCVkeHUh?=
LXF-289 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjrUlBKSzVyPUCuPVU6ODFizszN MmXlV2FPT0WU
ES6 M{jNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT0TWM2OD1yLkm2OFM4KM7:TR?= NEjTXotUSU6JRWK=
OS-RC-2 NGTOZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LXe2lEPTB;MD65Olg{KM7:TR?= M2nvXnNCVkeHUh?=
DMS-153 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DVR2lEPTB;MD65O|Q3QSEQvF2= NWrN[pZrW0GQR1XS
SK-PN-DW NF7kTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwOUe4N|Eh|ryP MXrTRW5ITVJ?
HH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LSc2lEPTB;MD65PFk2QSEQvF2= MX;TRW5ITVJ?
SH-4 M1;MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvQc4p[UUN3ME2xMlAzPDFizszN MUHTRW5ITVJ?
MOLT-4 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLqTWM2OD1zLkCzOFU1KM7:TR?= M4\WTHNCVkeHUh?=
TGW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMEe2O|Uh|ryP Mne4V2FPT0WU
L-540 M3;w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHJTWM2OD1zLkGwOlA1KM7:TR?= NFHXNW1USU6JRWK=
PF-382 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsTWM2OD1zLkGxOVE{KM7:TR?= MofEV2FPT0WU
LC-1F M1HIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPNSVI6UUN3ME2xMlEzODB5IN88US=> M1fjZ3NCVkeHUh?=
OVCAR-4 NFHzc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnftTWM2OD1zLkGzNVY2KM7:TR?= MUDTRW5ITVJ?
A4-Fuk NUfselBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnRcHFKSzVyPUGuNVU{PjRizszN MkLZV2FPT0WU
HCC2218 NHfO[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHBTWM2OD1zLkG2OlQyKM7:TR?= NF;oU2FUSU6JRWK=
HAL-01 NHjHNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r1fGlEPTB;MT6xOlk1OyEQvF2= MoDNV2FPT0WU
IST-MEL1 M{HtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwMUe2OVkh|ryP NYe1PId3W0GQR1XS
NCI-H719 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwMUe4PVgh|ryP NY\DTIsyW0GQR1XS
EVSA-T M17wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\Ie5FKSzVyPUGuNVgyOTRizszN NV7WUlczW0GQR1XS
SK-NEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED5NIFKSzVyPUGuNlAzPjZizszN NFv0RnhUSU6JRWK=
OCUB-M MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M334VGlEPTB;MT6yNVQ5QSEQvF2= MkO4V2FPT0WU
MEG-01 NFfzS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTpTWM2OD1zLkKyNVE5KM7:TR?= NGC3WoRUSU6JRWK=
no-10 M1;u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHaTWM2OD1zLkKzNVEzKM7:TR?= M4jOeXNCVkeHUh?=
MHH-CALL-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLGTWM2OD1zLkK0O|IyKM7:TR?= MUDTRW5ITVJ?
SK-N-DZ NVPpZlNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\3emlEPTB;MT6yOFc4PiEQvF2= M{n6XHNCVkeHUh?=
SCLC-21H NX3r[XZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPLdm1ZUUN3ME2xMlI3PDd6IN88US=> NHnY[5JUSU6JRWK=
CTV-1 NW\1dHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwMke0NlUh|ryP MkXFV2FPT0WU
NB1 NEfuNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLlVppMUUN3ME2xMlI4PzN{IN88US=> Mn3IV2FPT0WU
NCI-H64 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTTZmlKSzVyPUGuNlg1PjJizszN MVHTRW5ITVJ?
MDA-MB-134-VI NVzk[|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljsTWM2OD1zLkK4OVc4KM7:TR?= MWnTRW5ITVJ?
LB2241-RCC NHK1[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvPU|NKSzVyPUGuNlg3PjNizszN NVXBdW45W0GQR1XS
8-MG-BA MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS0TWM2OD1zLkK4PFY3KM7:TR?= MU\TRW5ITVJ?
LP-1 NVflR5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwMkm5OFch|ryP NEXSVohUSU6JRWK=
LS-411N M16xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknDTWM2OD1zLkOwPVk5KM7:TR?= MUPTRW5ITVJ?
CAL-148 NX3peJVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfxR3R7UUN3ME2xMlMzPTR{IN88US=> MkDRV2FPT0WU
NCI-H2171 M3rBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKwbGpUUUN3ME2xMlM1PTB{IN88US=> NVSxVm5FW0GQR1XS
JiyoyeP-2003 NUnxPXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDHTWM2OD1zLkO1N|kh|ryP M3znSnNCVkeHUh?=
NCI-H2107 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHtdJJDUUN3ME2xMlM2QDh|IN88US=> NF7XNlBUSU6JRWK=
BB30-HNC MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwM{i5O|gh|ryP M2S5UXNCVkeHUh?=
K-562 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7kTWM2OD1zLkO5NlE6KM7:TR?= NWOwT4poW0GQR1XS
PSN1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwNEKyPFch|ryP MXzTRW5ITVJ?
HCC2157 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK1TWM2OD1zLkSyOlkyKM7:TR?= NGTvVFRUSU6JRWK=
SBC-1 NHm4VoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwNEK3OFEh|ryP NEjURlRUSU6JRWK=
MC116 NEnneXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonITWM2OD1zLkSzOlE2KM7:TR?= M1fIPXNCVkeHUh?=
KARPAS-422 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LVcWlEPTB;MT60OVM2QCEQvF2= NV7UNI5mW0GQR1XS
LB996-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwNEexNFMh|ryP NHPQd|ZUSU6JRWK=
MSTO-211H NHjwVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPqUpNUUUN3ME2xMlQ4QTh5IN88US=> NFTS[nRUSU6JRWK=
BT-474 M2DHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwNUG3OlQh|ryP M4fPWXNCVkeHUh?=
A388 NHPNR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwNUG5OFUh|ryP NGXPV2hUSU6JRWK=
SJSA-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPCXGxJUUN3ME2xMlUzOjZizszN MWDTRW5ITVJ?
COLO-829 NESyWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLvN4JKSzVyPUGuOVM2PjRizszN MYTTRW5ITVJ?
KM-H2 M2XESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jpSmlEPTB;MT61OlY4KM7:TR?= MojkV2FPT0WU
GR-ST MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\qO5ZKSzVyPUGuOVY5OiEQvF2= MkHuV2FPT0WU
RPMI-8866 NFnXd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rU[GlEPTB;MT62NFE1PCEQvF2= NUHhUVdSW0GQR1XS
KG-1 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrMTWM2OD1zLk[xPVAyKM7:TR?= NH[zPYxUSU6JRWK=
NCI-H82 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHnXnU6UUN3ME2xMlY{PDB4IN88US=> NHz1TWFUSU6JRWK=
LB1047-RCC NHvqTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjTTWM2OD1zLk[zOFU6KM7:TR?= MnnzV2FPT0WU
KM12 NVjWfXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDvdIhKSzVyPUGuOlQ4KM7:TR?= MknFV2FPT0WU
NB5 NGDkeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwNkW2O|ch|ryP MYjTRW5ITVJ?
HDLM-2 M3PGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n1XWlEPTB;MT62PFI5OSEQvF2= MYHTRW5ITVJ?
KU812 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xy[WlEPTB;MT62PVYxPSEQvF2= MUTTRW5ITVJ?
DB Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwN{CzOVMh|ryP NYS1foZ{W0GQR1XS
HD-MY-Z MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjsTWM2OD1zLke1NlM1KM7:TR?= NHfOcW9USU6JRWK=
KURAMOCHI M1zrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv2RXg3UUN3ME2xMlc4OjB5IN88US=> NH3nRVZUSU6JRWK=
ETK-1 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPsOZlHUUN3ME2xMlc5QDd7IN88US=> NXHn[HM{W0GQR1XS
SK-UT-1 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwN{mzPFgh|ryP NULze243W0GQR1XS
HUTU-80 NV73S4FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfSWnRuUUN3ME2xMlc6PTB6IN88US=> MWDTRW5ITVJ?
ES7 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HvUWlEPTB;MT64NFMxOiEQvF2= NEXJWmlUSU6JRWK=
SW872 NXLWOFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;UZ|F1UUN3ME2xMlgyOzl3IN88US=> NWfz[3ZpW0GQR1XS
TK10 NWm4OHRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fDR2lEPTB;MT64N|ExQCEQvF2= NH\kbllUSU6JRWK=
LB831-BLC NEHZT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTIPGJ{UUN3ME2xMlg{PTZ|IN88US=> MVrTRW5ITVJ?
TE-9 NHXDPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[wc2lEPTB;MT64OFQzOiEQvF2= M2LMT3NCVkeHUh?=
MLMA NX33WGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwOEiyN|Qh|ryP NYHnXHJCW0GQR1XS
D-542MG NXXOcG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:wRpZEUUN3ME2xMlg6Ozd|IN88US=> MnjyV2FPT0WU
EW-16 NHv1TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6PWlEPTB;MT65NlczKM7:TR?= NI\mTXdUSU6JRWK=
LOXIMVI M3nuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXsSGFMUUN3ME2xMlk{OjhizszN M4DkfXNCVkeHUh?=
GB-1 NXOzRo86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:4emtKSzVyPUGuPVM5PjZizszN M1;YTnNCVkeHUh?=
IST-SL2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD2UIsxUUN3ME2yMlAxOjZ{IN88US=> MnTKV2FPT0WU
LAN-6 NYXhcnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H6[WlEPTB;Mj6wNVk3PiEQvF2= NHzPTYJUSU6JRWK=
NCI-H510A NYi0PGRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P4dWlEPTB;Mj6wOFUxOiEQvF2= M1ryeHNCVkeHUh?=
NCI-H1092 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQfZFtUUN3ME2yMlA2OTJ2IN88US=> M4ru[nNCVkeHUh?=
HT M1;xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwMUC0OVQh|ryP Mn;GV2FPT0WU
RL95-2 NU[4dlU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmyTWM2OD1{LkGxOFgzKM7:TR?= MYLTRW5ITVJ?
NCI-H1355 M{O5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPwU4x[UUN3ME2yMlEyPzl{IN88US=> NVfIPZoyW0GQR1XS
NCI-H720 M{G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rEbWlEPTB;Mj6xOlg4OyEQvF2= MXLTRW5ITVJ?
NCI-H1522 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PYW2lEPTB;Mj6yNVczOyEQvF2= M1rvdXNCVkeHUh?=
LB373-MEL-D M3ftS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3jUFBxUUN3ME2yMlI3QTB{IN88US=> MnvGV2FPT0WU
DG-75 M4LKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMkexOFgh|ryP MXzTRW5ITVJ?
ML-2 M{DybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq1bIlKSzVyPUKuN|I5PTVizszN MmPlV2FPT0WU
SF126 M4PydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfjfVJVUUN3ME2yMlM{ODl2IN88US=> MUfTRW5ITVJ?
MPP-89 NFm1XYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW1TWM2OD1{LkOzNVQ2KM7:TR?= M4LXTnNCVkeHUh?=
NCI-H345 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vpbWlEPTB;Mj6zN|I4PyEQvF2= MoLPV2FPT0WU
LS-123 M2jiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLRTWM2OD1{LkO0PVM3KM7:TR?= M2q1VHNCVkeHUh?=
NB10 NFTqZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW1cmlUUUN3ME2yMlQyODl{IN88US=> MnPmV2FPT0WU
CGTH-W-1 NFL0VYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLpTWM2OD1{LkSyNlY4KM7:TR?= NVzmXmRXW0GQR1XS
CP66-MEL M1vaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q0[mlEPTB;Mj60O|c4KM7:TR?= MWDTRW5ITVJ?
L-428 NYrTbGtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT6eIFKSzVyPUKuOFg2OjFizszN NFS2fXNUSU6JRWK=
DMS-79 NHzxR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHTblRKSzVyPUKuOVQyODNizszN NIrLW41USU6JRWK=
NCI-H1882 NEHweFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy5XoFIUUN3ME2yMlY4PTZ{IN88US=> MV;TRW5ITVJ?
KGN M4HSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7hUoVKSzVyPUKuO|Y5PzZizszN MoDxV2FPT0WU
EW-1 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LKZmlEPTB;Mj63O|A5OyEQvF2= NEK4clFUSU6JRWK=
U-266 NVjPVpBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW1SG5MUUN3ME2yMlg1QDJ|IN88US=> M4HKVnNCVkeHUh?=
COLO-320-HSR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDvcINsUUN3ME2yMlg2PjRzIN88US=> MYjTRW5ITVJ?
KMOE-2 NX3P[XBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUntN2NYUUN3ME2yMlg4PzFzIN88US=> M4HyN3NCVkeHUh?=
BB49-HNC M2nQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HNdWlEPTB;Mj65NlQ5KM7:TR?= MkXWV2FPT0WU
GI-1 NFLMdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e0N2lEPTB;Mj65Nlk2PyEQvF2= NWD4dWdRW0GQR1XS
NCI-H1304 M1rHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVizNm1RUUN3ME2zMlAxPTFzIN88US=> MkXCV2FPT0WU
NCI-H2227 NHj4OoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2wTZhKSzVyPUOuNFIxPzlizszN MV7TRW5ITVJ?
U-87-MG NHf2epJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCzTWM2OD1|LkCzOVE{KM7:TR?= NVPofJdFW0GQR1XS
NCI-H747 NYXaZnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[xPJlKSzVyPUOuNFUzODZizszN M3nmbXNCVkeHUh?=
CTB-1 NWjHPIFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXizN4FNUUN3ME2zMlA2Ozd4IN88US=> M1v0dXNCVkeHUh?=
RPMI-8226 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VPFlKSzVyPUOuNVQ{PzhizszN MU\TRW5ITVJ?
NCI-H2141 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHhZ45KSzVyPUOuNVY2PjZizszN MnK0V2FPT0WU
IST-MES1 NWPDRYh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwMUiyO|kh|ryP M{Sx[nNCVkeHUh?=
TE-5 M{e4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqxTHpKSzVyPUOuNlE{PDJizszN NYK0W|FXW0GQR1XS
UACC-257 NWXUV4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u3OGlEPTB;Mz60N|Y2QSEQvF2= M2nu[nNCVkeHUh?=
SK-N-FI Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNwNEWyNlch|ryP MlrjV2FPT0WU
MFH-ino MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTWTWM2OD1|LkS2OVg6KM7:TR?= MnvVV2FPT0WU
SF268 NG\XWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q5RmlEPTB;Mz60PFE4PCEQvF2= MmK2V2FPT0WU
TE-12 NITNN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP3TWM2OD1|LkWxOlk6KM7:TR?= NV3aeZYxW0GQR1XS
NB6 M13SSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7pO28yUUN3ME2zMlU2PTZ|IN88US=> MoL5V2FPT0WU
DJM-1 M2rZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljaTWM2OD1|LkW5PFk6KM7:TR?= M{jzfHNCVkeHUh?=
MZ1-PC NUf3cm12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHkTWM2OD1|Lk[xOlI1KM7:TR?= NHzlUZBUSU6JRWK=
OCI-AML2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17nNWlEPTB;Mz62NlY4OSEQvF2= NXjTZZM6W0GQR1XS
NCI-H1155 NYHtRWRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnKbIVKSzVyPUOuO|A6PDdizszN NIXoZmVUSU6JRWK=
RKO MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXnVVVKSzVyPUOuO|cyQDlizszN MWrTRW5ITVJ?
ECC4 NXLGZVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNwOUexPVUh|ryP MVLTRW5ITVJ?
BB65-RCC M1PxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwOUe1OFch|ryP MWnTRW5ITVJ?
EB-3 NVTK[I5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNwOUm2N|Mh|ryP MnHnV2FPT0WU
SHP-77 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[1W2NNUUN3ME20MlAxPTJ2IN88US=> MkL4V2FPT0WU
NCI-H2196 NGftN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmyOWVTUUN3ME20MlA2PjJ3IN88US=> NEXIfXdUSU6JRWK=
GI-ME-N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XvdGlEPTB;ND6wOlM6QSEQvF2= MYLTRW5ITVJ?
MN-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRwMUC4O{DPxE1? M2XmNXNCVkeHUh?=
NCI-H1694 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7zTWM2OD12LkGzOFA2KM7:TR?= NGLNVGlUSU6JRWK=
LU-65 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33icGlEPTB;ND6xOVM{OiEQvF2= MYXTRW5ITVJ?
NCI-H1436 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwMUizN|Mh|ryP MkDBV2FPT0WU
KINGS-1 NHPzUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;TeVJKUUN3ME20MlMyPDN{IN88US=> NFfnc3hUSU6JRWK=
GT3TKB Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25VFhwUUN3ME20MlM{OjZ6IN88US=> MmHzV2FPT0WU
Becker NVnQUGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7XRmVKSzVyPUSuN|c{OTJizszN NVH4cpI4W0GQR1XS
HCC1187 M2\GRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3GZnlKSzVyPUSuPFk3PTdizszN NEDtbZJUSU6JRWK=
D-502MG MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DnWWlEPTB;NT6wNFQyPiEQvF2= MWPTRW5ITVJ?
VA-ES-BJ MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HO[GlEPTB;NT6xN|c4QCEQvF2= NEDz[m9USU6JRWK=
NB7 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\aTXZKSzVyPUWuNVQyOTJizszN M{izc3NCVkeHUh?=
SW962 NUnVTWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojXTWM2OD13LkO4PFE1KM7:TR?= MWHTRW5ITVJ?
no-11 NUj5WYtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;TZ3dZUUN3ME21Mlc3OzR|IN88US=> NWjBNWFEW0GQR1XS
KNS-81-FD MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED1TGNKSzVyPUWuPVA3QTRizszN M3TlXnNCVkeHUh?=
COLO-684 NVLPelVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{iwfmlEPTB;NT65PVQ6PCEQvF2= NYPreotbW0GQR1XS
D-263MG NXHWOZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLkTWM2OD14LkC4PFk2KM7:TR?= MVnTRW5ITVJ?
EW-24 NEX2VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD14LkK4OVEh|ryP MWfTRW5ITVJ?
TE-10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfmdXVKSzVyPU[uOFI3OjNizszN NUnwRopNW0GQR1XS
EKVX Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zEd2lEPTB;Nj60OlMzOSEQvF2= MnrMV2FPT0WU
NCI-H1648 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHRT4F2UUN3ME22MlY4PTV5IN88US=> NIn4[29USU6JRWK=
LB771-HNC MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\wbFFIUUN3ME22MlkzOzBzIN88US=> NF;LO2RUSU6JRWK=
SK-MEL-1 NWnlN2pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3qZVFkUUN3ME24MlE{OTZ4IN88US=> MXXTRW5ITVJ?
COLO-668 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRThwMke3PFYh|ryP M1P5O3NCVkeHUh?=
EW-12 NG[xRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjRb2dbUUN3ME24MlQxQDB|IN88US=> MoDDV2FPT0WU
A253 NYPxZnVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjwTWM2OD16Lki0OlYyKM7:TR?= NV3MdoQ4W0GQR1XS
NCI-H2126 NHLHXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXjRnpEUUN3ME24Mlg6OzF7IN88US=> NVr0N3V5W0GQR1XS
Calu-6 NY\mcmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzyPXFKSzVyPUiuPVkxPDJizszN MkLEV2FPT0WU
NCI-H23 M3uyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjWbIFRUUN3ME25MlE4PzR4IN88US=> NWm3cJZVW0GQR1XS
WSU-NHL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS1bVdKSzVyPUmuO|c1PzhizszN MmLVV2FPT0WU
MMAC-SF NF7zd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPzU25KSzVyPUmuPVc6ODRizszN MYjTRW5ITVJ?
SK-LMS-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFyLkK4N|Qh|ryP MYXTRW5ITVJ?
GCIY Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD1zMD61PVI1KM7:TR?= NVGxd4Q5W0GQR1XS
TE-15 NX:zbJdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELGeHlKSzVyPUGxMlYxODRizszN NXTKTGFnW0GQR1XS
EoL-1-cell NYC4fo5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfmcm13UUN3ME2xNU44Pjh{IN88US=> MVPTRW5ITVJ?
NCI-H2081 NGLnUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVdHJKSzVyPUGxMlc4QDZizszN NWGyS2x[W0GQR1XS
EW-3 NIW3[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF{LkK0OlMh|ryP M13SXXNCVkeHUh?=
CAS-1 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lu[WlEPTB;MUKuN|Y{OSEQvF2= M3;CV3NCVkeHUh?=
C2BBe1 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF{Lk[xN|Eh|ryP M1T3T3NCVkeHUh?=
D-247MG NY\wZnc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG2RXlKSzVyPUGyMlc6PTJizszN NYO0VZc{W0GQR1XS
NCI-SNU-5 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnWPIdEUUN3ME2xNk45ODF|IN88US=> M3;vPHNCVkeHUh?=
LS-1034 NFjxXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF2LkO5O|Uh|ryP NFXucZNUSU6JRWK=
EW-18 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn4TWM2OD1zND60OFgh|ryP NVPucW5rW0GQR1XS
Raji M{fpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT5TWM2OD1zND61NFQ6KM7:TR?= NIXZfndUSU6JRWK=
D-283MED NUnkWIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrGTWM2OD1zND62NlcyKM7:TR?= NX\TVZZ3W0GQR1XS
MZ2-MEL M1PpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H2W2lEPTB;MUSuPVY6PiEQvF2= MVLTRW5ITVJ?
NCI-SNU-16 M{W4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HGNmlEPTB;MUWuOFY{OyEQvF2= MnvRV2FPT0WU
P30-OHK NYjaOYpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF5Lke4N|Eh|ryP MWDTRW5ITVJ?
RXF393 M2Lkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzSZoxGUUN3ME2xPU4xOTh4IN88US=> NGP1Sm1USU6JRWK=
NCI-H1395 MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfyXIdKSzVyPUKwMlY4ODNizszN MVLTRW5ITVJ?
U-698-M MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTZOmpKSzVyPUKwMlcxPzVizszN MVjTRW5ITVJ?
NCI-SNU-1 M1rxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJTWM2OD1{MD63NlI{KM7:TR?= MY\TRW5ITVJ?
SW684 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1WJFKSzVyPUKxMlE4OTZizszN NUjaSVBJW0GQR1XS
NCI-H716 NH\GWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzleJdKSzVyPUKxMlMyPTRizszN NXrUUXFCW0GQR1XS
JVM-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXrTWM2OD1{MT60NVM{KM7:TR?= NVXTU2gzW0GQR1XS
NCI-H1581 NVXocWt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki3TWM2OD1{Mj60NVQ5KM7:TR?= NF3vPFJUSU6JRWK=
CA46 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrFbGU3UUN3ME2zNU43QTN4IN88US=> MU\TRW5ITVJ?
SNB75 NWT1UZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEThV3dKSzVyPUOzMlY2ODNizszN NWDmfHEzW0GQR1XS
KNS-42 NGXZZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fMOWlEPTB;M{WuPVYzPCEQvF2= NGj4Z3BUSU6JRWK=
TUR MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3YTWM2OD1|Nj6wOVIyKM7:TR?= M1W3SXNCVkeHUh?=
REH NH;td4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPVbHVKSzVyPUO3MlgzOTFizszN MVfTRW5ITVJ?
EW-22 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP3bXhKSzVyPUSyMlI5QDVizszN NF6zXGFUSU6JRWK=
NCI-H446 NEG4OFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDsXZlKSzVyPUSyMlc5PTNizszN M4fQ[HNCVkeHUh?=
ES3 NXvhc2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jzRWlEPTB;NEOuNVM{QSEQvF2= MVHTRW5ITVJ?
EW-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR2LkiyNVgh|ryP NUn1Zo9jW0GQR1XS
RH-1 NHHRbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[zUWNKSzVyPUS3MlU5OTJizszN NFHEUolUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID